HK Stock Market Move | XTALPI(02228) is currently up more than 4%, achieving its first annual profit in 2025. The valuable AI pharmaceutical platform is accelerating its realization.

XTALPI (02228) is currently up by more than 4%. As of the time of writing, it is up by 4%, trading at 9.88 Hong Kong dollars, with a trading volume of 3.83 billion Hong Kong dollars. On the news front, XTALPI previously announced a profit forecast, expecting the company to achieve a revenue of no less than 780 million yuan in 2025, a year-on-year growth of over 193%; the net profit attributable to shareholders will be no less than 100 million yuan, turning losses into profits year-on-year, and achieving full-year profitability for the first time. Guolian Minsheng released a research report stating that the performance in 2025 is impressive, and the value of the scarce AI pharmaceutical platform is accelerating realization. GF SEC pointed out that in early 2026, XTALPI reached cooperation agreements with leaders in various industries, delivering automation and AI solutions to chemical giant BASF, and South Korean company JW Pharmaceutical, in collaboration with Siasun Robot&Automation and ReviR Xili Technology, jointly developed the first domestic "AI+RNA" small molecule innovative drug RTX-117. It has completed the first patient dosing and entered the clinical development stage, deepening cooperation in sub-sectors such as endocrine drugs, mRNA, and self-immunity with companies such as SUNSHINE PHARMA, Wising Pharmaceutical, Yaotang Biological, and Morda Bio.